InTechOpen uses cookies to offer you the best online experience. By continuing to use our site, you agree to our Privacy Policy.

Medicine » Endocrinology and Metabolism » "Medical Complications of Type 2 Diabetes", book edited by Colleen Croniger, ISBN 978-953-307-363-7, Published: September 12, 2011 under CC BY-NC-SA 3.0 license. © The Author(s).

Chapter 15

Can Bariatric or Metabolic Surgery Cure Type 2 Diabetes?

By Gustavo P. S. Miguel, Perseu Carvalho, João Luiz Azevedo, Murilo Hosken Júnior, Évelyn Zambrana, Otávio Azevedo and Isaac Abreu
DOI: 10.5772/22544

Article top


Preoperative and postoperative fasting glucose levels mg/dl (p < 0.001).
Figure 1. Preoperative and postoperative fasting glucose levels mg/dl (p < 0.001).
Progress of glucose homeostasis and treatment of the patients submitted to surgery.
Figure 2. Progress of glucose homeostasis and treatment of the patients submitted to surgery.

Can Bariatric or Metabolic Surgery Cure Type 2 Diabetes?

Gustavo P. S. Miguel1, Perseu Carvalho1, João Luiz Azevedo1, Murilo Hosken Júnior1, Évelyn Zambrana1, Otávio Azevedo 1 and Isaac Abreu1

1. Introduction

Obesity is a multifactorial disease that affects millions of people worldwide. It is the main independent risk factor for developing type 2 diabetes mellitus (T2DM).(1,2) Most patients with T2DM and glucose intolerance (GI) are overweight, a condition known as diabesity.2(,3) In patients with the most severe form of obesity, i.e. morbid obesity, the likelihood of developing diseases associated with obesity is increased.(1,4)

We currently know that bariatric surgery provides sustained weight loss and well-documented remission of T2DM.(5,6) Patients who undergo bariatric surgery show long-term reduced mortality(7) from coronary artery disease, cancer and diabetes; 136 lives are saved per 10,000 surgical procedures performed.(8) Bariatric surgery is a relatively safe procedure that is becoming increasingly well-accepted; in 2007, approximately 170,000 bariatric procedures were performed in the USA.(6) Currently, bariatric surgery is the most effective choice of treatment of morbidly obese patients with diabetes.9

The surgical procedures that are currently performed to treat morbid obesity are divided into two main groups: gastric restrictive procedures and combination procedures; the latter combine gastric restriction and malabsorption.(10) The roux-en-Y gastric bypass (RYGB) is the combination procedure most frequently performed,(7,11) whereas sleeve gastrectomy (SG) is an emerging restrictive procedure.(12) SG can be performed as the first of a two-stage operation in patients at high risk of death,(13,14) or as a definitive surgical procedure.(15) It has shown good results with regard to weight loss(16) and glycemic control in various studies.(6,14,16,17) The potential advantages of SG include lower probability of vitamin and mineral deficiencies because this procedure has no malabsorptive component; access to the entire intestinal tract; no need for a subcutaneous access port or adjustments; absence of dumping syndrome and lower probability of intestinal obstruction. In addition, SG can be performed in patients who have inflammatory bowel disease or who have undergone bowel surgery, and it can be easily converted into RYGB.(12,15) Both SG and RYGB can be performed with or without the placement of a Silastic® ring.(18,19)

The metabolic control achieved with bariatric procedures has been demonstrated and reproduced in various medical centers worldwide.(6) Metabolic control can be achieved with gastric restrictive procedures such as vertical banded gastroplasty,(5) adjustable gastric banding(20) and, more recently, SG.(17) However, it has been shown that glucose homeostasis is affected by various intestinal mechanisms observed exclusively in procedures that include a malabsorptive element,(21) such as RYGB.(22-24)

A systematic review of 22,094 cases of morbidly obese patients submitted to bariatric surgery has shown that resolution of T2DM was achieved in 76.8% of the cases, improvement being achieved in 86% of cases.(25) Among the criteria used to diagnose metabolic syndrome, fasting glucose levels(26) are the first to return to normal in patients submitted to Silastic® ring gastric bypass (SRGB), a modification of the traditional RYGB which consists in adding a Silastic® ring to the gastric bypass operation. Normoglycemia after bariatric procedures, as well as diabesity itself, (27,28) is multifactorial.(6,29,30) Normoglycemia is observed as a result of dietary control,(20,21) decreased plasma levels of ghrelin,(32) weight loss and reduction of body fat(6), as well as of the release of gastrointestinal hormones that interfere with the function of pancreatic β cells (incretins).(23,24,33,34)

To compare the weight loss of morbidly obese patients submitted to either a Silastic® ring sleeve gastrectomy (SRSG) or an SRGB, as well as to compare the effects of both procedures on glucose homeostasis in morbidly obese patients, our research group developed a study that will be better described ahead.

2. Methods

2.1. Study protocol

This was a non-randomized, prospective, controlled clinical study. It was approved by the Research Ethics Committee of the University Hospital of the Federal University of Espírito Santo, Brazil (protocol no. 049/06) and registered in, identifier NCT00873405. In order to homogenize the sample, we adopted the following inclusion criteria: female patients aged 20-60 years, with BMI 40-45 (inclusive), who agreed on giving written informed consent. The exclusion criteria adopted were secondary obesity, alcohol or drug use, severe psychiatric disorder, binge-eating of sweets and previous stomach or bowel surgery.

2.2. Sample

Sixty-five female patients were included in the present study. The patients had a mean age of 36.03 years, mean BMI of 42.47 and mean waist circumference of 119.62 cm. Mean preoperative fasting glucose levels were 103.38 mg/dL (Table 1).

VariablesMean, SD, minimum value, maximum value
Age (years)36.03 ± 9.18 (20-59)
Body mass index (kg/m2)42.47 ± 1.64 (40-45)
Waist circumference (cm)119.62 ± 8.06 (100-140)
Fasting glucose levels (mg/dL)103.38 ± 36.5 (70-320)

Table 1.

Anthropometric data and preoperative fasting glucose levels.

The diagnoses of diabetes and GI were based on the criteria adopted by the Brazilian Diabetes Society.(35) T2DM was found in 14 patients (21,5%) and GI, a transitional state to diabetes itself, was found in 12 patients (18,5%). Therefore, 40% of the morbidly obese patients analyzed in the present study presented with elevated fasting glucose levels (Table 2).

Fasting glucose levelsn%
Glucose intolerance1218,5%

Table 2.

Prevalence of preoperative type 2 diabetes mellitus and glucose intolerance.

Most of the diabetic patients used oral hypoglycemic agents (Table 3).

OHG + Insulin12%

Table 3.

Preoperative antidiabetic therapy.HG – oral hypoglycemic agent

The 65 patients were divided into two groups; 33 patients (51%) were submitted to SRSG (SRSG group), whereas 32 (49%) patients were submitted to SRGB (SRGB group). Assessment was performed again 12 to 14 months after the surgery.

2.3. Surgical procedure

The surgical procedures were performed between December 08, 2006 and July 27, 2007 at Hospital Universitário Cassiano Antonio Moraes from the Universidade Federal do Espírito Santo (HUCAM/UFES, Cassiano Antonio Moraes University Hospital, Federal University of Espírito Santo). The procedures were performed by the same surgeon using a similar anesthetic technique (peridural anesthesia combined with general anesthesia).

The patients from the SRSG group were submitted to the following procedures: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.

The patients of the SRGB group were submitted to the following procedures: creation of a small, proximal gastric pouch and exclusion of a large part of the stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.

In both groups, the stapled lines were sutured and a methylene blue test was performed to verify whether the staple line was secure. The patients were given a liquid diet on the first postoperative day and were to be discharged on the third postoperative day. They received dietary guidance and instructions regarding physical activities. In addition, patients from both groups were prescribed similar vitamin and mineral supplementation.


Weight loss, BMI reduction and waist circumference reduction were assessed. The percentage of excess BMI loss was calculated as follows: preoperative BMI - current BMI ÷ preoperative BMI - 25 × 100.(36) Glucose homeostasis was assessed through the measurement of fasting glucose levels after the interruption of the pharmacological treatment.

2.5. Statistical analysis

Descriptive analysis was conducted and the results were expressed as means, standard deviations, medians, frequency (%), minimum values and maximum values. The Mann-Whitney test was applied to assess sample variation and homogeneity between groups. Fisher’s exact test and chi-square test were employed to compare the results between the two groups. The ANOVA was used to assess glucose levels according to time and groups. Statistical significance was set at p < 0.05.

2.6. Results

In the preoperative period, no significant difference in age, BMI or waist circumference was found between patients from the SRSG group and patients from the SRGB group (Table 4).

VariableGroupMean, SD, minimum value, maximum value*
AgeSRSG36.70 ± 9.4 (20-59)
SRGB35.34 ± 9.04 (21-58)
BMISRSG42.33 ± 1.5 (40-45)
SRGB42.62 ± 1.78 (40.3-44.9)
Waist circumference (cm)SRSG118.70 ± 5.98 (107-131)
SRGB120.58 ± 9.76 (100-140)

Table 4.

Comparison of age, preoperative body mass index and preoperative waist circumference between the groups.BMI: body mass index. SRSG: Silastic® ring sleeve gastrectomy. SRGB: Silastic® ring gastric bypass. *No significant difference was observed between the groups.

Considering the entire sample, BMI decreased from 42.47 to 27.5 ± 2.67 (p < 0.05). Excess BMI loss was 86.18 ± 15% (46.6 – 114.6). In addition, we observed a reduction in waist circumference from 119.62 to 90.38 ± 7.9 cm (74 – 108) (p < 0.05). The results obtained with both surgical procedures were similar with regard to weight loss, BMI reduction, excess BMI loss and waist circumference reduction (Table 5).

Weight loss (%)- 34.65 (6.43)- 35.32 (6.20)0.751
BMI loss (%)- 35.11 (6.03)- 35.35 (6.22)0.893
Excess BMI loss86.51 (14.20)85.86 (15.97)0.954
waist circumference
reduction (%)
- 23.98 (5.42)- 23.95 (7.86)0.626

Table 5.

Comparison of weight loss, BMI reduction, percentage of excess BMI reduction and waist circumference reduction between the groups.BMI = body mass index. SRSG: Silastic® ring sleeve gastrectomy. SRGB: Silastic® ring gastric bypass.

Decreased fasting glucose levels were observed in the postoperative period (p < 0.001), as shown in Figure 1.


Figure 1.

Preoperative and postoperative fasting glucose levels mg/dl (p < 0.001).

This decrease was similar in both groups (Table 6).

Group*Period**Fasting glucose levels
SRSGPreoperative108.5 ± 43.76 (75-320)
Postoperative80.79 ± 6.47 (71-98)
SRGBPreoperative98.25 ± 27.18 (70-218)
Postoperative81.04 ± 5.22 (70-91)

Table 6.

Preoperative and postoperative fasting glucose levels for both groups.SRSG: Silastic® ring sleeve gastrectomy. SRGB: Silastic® ring gastric bypass. *No significant difference was observed between groups. **p < 0.001.

Both surgical procedures proved effective in promoting the resolution of T2DM and GI in the affected patients (p < 0.001), as shown in Table 7.

Preoperative T2DM and GIPreoperative T2DM and GITotal

Table 7.

Remission of type 2 diabetes mellitus and glucose intolerance in the patients affected submitted to surgery.T2DM: type 2 diabetes mellitus. GI: glucose intolerance. Groups vs. time, p < 0.001.

All of the patients were able to discontinue the use of oral hypoglycemic agents or insulin, or both, during the follow-up period (Figure 2).


Figure 2.

Progress of glucose homeostasis and treatment of the patients submitted to surgery.

Although it was not the main focus of the present study, it was noteworthy that a fistula was developed at the staple line in two (6%) SRSG group patients (p = 0.4936). Both patients required reoperation. One of these patients died and the other was submitted to total gastrectomy, which led to the resolution of the fistula.

2.7. Discussion

The SG procedure has been increasingly used in bariatric surgery.(12-17) However, there are few prospective clinical studies in the literature that compare that emerging procedure with the gold standard.(12,17)

In the present study, SG was performed and a Silastic® ring was placed around the stomach. We obtained a small, functional stomach, like that obtained with traditional vertical gastroplasty, and removed the principal site of ghrelin production, which gave the SRSG the characteristics of both bariatric and endocrine surgery.(19) The removal of the principal site of ghrelin production led to a decrease in ghrelin levels, adding a hormonal element to SRSG, which other restrictive procedures such as adjustable gastric banding lack.(31 ) Some authors have reported the use of added restriction in SG in order to increase the intensity and duration of weight loss(19,37,38). In addition, by placing a Silastic® ring around the stomach in all patients of our sample, both procedures became identical at the portion located above the ring.

Gastric bypass is the most used procedure in bariatric surgery and is considered by many the gold standard. Some researchers have reported that SG is less risky than RYGB.(12-14) However, in our sample, the most serious complications occurred in the SRSG group, which is, albeit not statistically significant, noteworthy.

Weight loss, BMI reduction, waist circumference reduction and excess BMI loss were expressive and similar in both groups. These findings are in accordance with those of some studies,(12,15,17) but in disagreement with those of other studies(13,14) that have regarded SG as the first stage of a definitive surgery. The good results of the present study are probably due to the judicious selection of the sample, which excluded BMI greater than 45 and patients with prior stomach or bowel surgery. In such cases, the results have been admittedly less effective. Other factors that might have contributed to the results of the present study include the calibration of the remaining stomach using a 32-Fr tube and the placement of a Silastic® ring. In other studies in which weight loss was less pronounced, tubes of greater caliber were used(39) and a Silastic® ring was not placed.(13,14)

Resolution of T2DM and decreased incidence of the disease have been well-documented in various types of bariatric surgery.(5) In two studies of patients submitted to SG, control of T2DM was achieved in 80% of the cases.(13,14) This remission rate was higher than that commonly reported for restrictive procedures such as vertical banded gastroplasty(5) and adjustable gastric banding;(20) it was, however, lower than that obtained with RYGB( 9,26) and biliopancreatic diversion procedures.(21)

In the study described above, the rate of clinical remission of GI and T2DM was similar for both groups of patients (100%). The reduction in blood glucose levels was also similar for both groups, a surprising result that has been reported in another study.(17). Because SRSG is basically a restrictive procedure that theoretically does not affect incretin expression, it was expected that the results obtained with this procedure would be inferior to those obtained after procedures with duodenal switch with regard to glucose homeostasis.(23,24,29,30) In the present study, glucose levels might have decreased as a result of the expressive weight loss observed in both groups, which led to increased sensitivity to insulin and decreased production of leptin, followed by increased insulin secretion and remission of GI and T2DM(40). Other hormones produced in the adipose tissue, such as resistin, might also have been involved in the glycemic control observed in the present study.(41,42)

We should also take into consideration that the patients submitted to surgery in the present study presented with mild GI or T2DM, the remission of which is more likely according to previous studies.22,24

The greatest limitation of our prospective, controlled study was the lack of randomization. This occurred because the Research Ethics Committee and the authors of this study considered that the often irreversible surgical procedures performed in the present study could not have been decided on without patient consent. A similar ethical issue was reported by the authors of the Swedish Obese Subjects study.5 In order to overcome such limitations we selected patients with rather similar characteristics. Both groups comprised patients with similar age, BMI, waist circumference and fasting glucose levels in the preoperative period. This translated to a superiority of this study over other studies conducted previously, in which the groups investigated were not similar,12 the sample was not homogeneous15 and the patients included often presented with BMI < 40 (12,15,17) and/or > 50.(12-17)

The surgical procedures performed in the present study, i.e. SRSG and SRGB, resulted in marked weight loss, BMI reduction, waist circumference reduction, excess BMI loss, improved glucose homeostasis and remission of GI and T2DM. These results were similar in both groups of morbidly obese patients. Further studies should be carried out adopting a longer follow-up period, as well as investigating other variables and possible hormonal changes, in order to consolidate SRSG.

With the satisfactory results obtained in the surgical treatment of T2DM through bariatric surgery in the last few years, has been evaluated the possibility of expanding the procedure indications for patients who are in a lesser degree of overweight. Such conduct has been accepted more liberally in patients with BMI between 30 and 35, but there are several clinical studies in subjects with BMI between 25 and 30. Recently, the IDF (International Diabetes Federation) classified as eligible for metabolic surgery, T2DM patients with BMI between 30 and 35.43

An Australian study, including patients with BMI between 30 and 40, comparing the intervention adjustable gastric band vs conventional therapy had remission of T2DM in 73% of the subjects against 13% in patients who underwent conventional therapy, with improvement in glucose levels, reduction of glycated hemoglobin and decrease of insulin plasma levels, demonstrating an improvement in insulinic sensitivity, measured by HOMA IR.44

Preliminary study report using the operation called laparoscopic mini-gastric bypass, performed in patients with BMI between 25 and 30, produced the resolution of hyperglycemia in 70% of operated patients.45

Double-blind randomized controlled trial including patients with BMI between 25 and 35 comparing the operations of gastric bypass vs sleeve gastrectomy showed remission of T2DM in both groups. However, the sleeve gastrectomy group remission occurred in 47% of patients and gastric bypass in group 93%. Demonstrating the superiority of gastric bypass in individuals with less overweight, probably due to the incretin action and the activity reduction of dipeptidyl peptidase-4.46

It should be noted in those patients with BMI between 25 and 35 the importance of a more detailed investigation in terms of T2DM pathogenesis, in order to reduce the possibility of submitting to surgery patients with complete failure of beta cells or autoimmune disease (DMT1ou LADA - Late autoimmune diabetes of adult). The preoperative evaluation of these patients should include: concentration of peptide C and tests for markers of pancreatic autoimmunity, as anti-glutamic acid dearboxylase (GAD) antibody and anti- Langerhans islet antibody.

3. Conclusion

The bariatric-metabolic surgery has unquestionable role in remission (cure?) of T2DM in subjects with BMI greater than 35. In this group of patients seems to be no difference in remission rates of T2DM between subjects undergoing gastric bypass or sleeve gastrectomy.

In subjects with less overweight, BMI between 30 and 35, nowadays eligible for metabolic surgery, gastric bypass seems to be more effective in producing remission of T2DM.

The metabolic surgery in patients with BMI between 25 and 30, still investigational, seems to show promising results in remission of T2DM, but further studies should be carried out to define its actual role.


1 - North American Association for the Study of Obesity (NAASO) and National Heart, Lung, and Blood Institute (NHLBI).The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH Publication #004084Oct 2000
2 - A. Must, J. Spadano, E. H. Coakley, A. E. Field, G. Colditz, W. H. Dietz, The disease burden associated with overweight and obesity. JAMA. 199928215231529
3 - M. B. Gomes, D. Giannella, E. Neto, M. A. De Mendonça, R. M. Tambascia, R. R. Fonseca, RéaPrevalência de sobrepeso e obesidade em pacientes com diabetes mellitus do tipo 2 no Brasil: Estudo multicêntrico nacional. Arq Bras Endocrinol Metab 20065013644
4 - K. M. Venkat, E. W. Narayan, A. Gregg, M. M. Fagot-Campagna, F. Engelgau, Diabetes. a. Vinicor, growing. common, costly. serious, preventable. potentially, health. public, problem, Diabetes: a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract. 2000S7784
5 - L. Sjöström, K. Narbro, D. Sjöström, K. Karason, B. Larsson, H. Wedel, et al.Effects of bariatric surgery on mortality in swedish obese subjects. N Engl J Med. 200735774152
6 - M. Bose, B. Oliván, J. Teixeira, F. X. Pi-Sunyer, B. Laferrère, Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence? Obes Surg. 20091921729
7 - N. V. Christou, J. S. Sampalis, M. Liberman, D. Look, S. Auger, A. P. H. Mc Lean, et al.Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg. 2004240416424
8 - T. D. Adams, R. E. Gress, S. C. Smith, R. C. Halverson, S. C. Simper, W. D. Rosamond, et al.Long-term mortality after gastric bypass surgery. N Engl J Med. 200735775361
9 - W. J. Pories, M. S. Swanson, K. G. Mac, S. B. Donald, P. G. Long, B. M. Morris, BrownWho would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995222339350
10 - H. Buchwald, J. N. Buchwald, Evolution of operative procedures for the management of morbid obesity, Obes Surg. 20021270517
11 - M. A. Fobi, Why the operation I prefer is silastic ring banded gastric bypass. Obes Surg. 199114236
12 - C.M. Lee, P.T. Cirangle, G.H. Jossart. Vertical gastrectomy for morbid obesity in 216 patients: report of two-year results. Surg Endosc. 2007. 21:1810-6
13 - D. Cottam, F. G. Qureshi, S. G. Mattar, S. Sharma, S. Holover, G. Bonanomi, et al.Laparoscopic sleeve gastrectomy as an initial weight-loss procedure for high-risk patients with morbid obesity. Surg Endosc 20062085963
14 - G. Silecchia, C. Boru, A. Pecchia, M. Rizzelo, G. Casella, F. Leonetti, et al.Effectiveness of laparoscopic sleeve gastrectomy (first stage of biliopancreatic diversion with duodenal switch) on co-morbidities in super-obese high-risk patients. Obes Surg 200616113844
15 - A. Baltasar, C. Serra, N. Perez, R. Bou, M. Bengochea, L. Ferri, sleeve. Laparoscopic, a. gastrectomy, bariatric. multi-purpose, operation, Obes Surg 200515811248
16 - S. Moon, W. W. Han, J. H. Kim, Oh, Results of laparoscopic sleeve gastrectomy (LSG) at 1 year in morbidly obese Korean patients. Obes Surg 200515146975
17 - J. Vidal, A. Ibarzabal, F. Romero, S. Delgado, D. Momblán, L. Flores, et al.. Type, mellitus. diabetes, metabolic. the, following. syndrome, gastrecmomy. sleeve, severely. in, subjects. obese, Obes Surg. 200818107782
18 - A. C. Valezi, E. M. Brito, J. C. L. Souza, A. L. M. Guariente, F. T. Emori, V. C. H. Lopes, A. importância, Rev Col Bras Cir. 2008351822
19 - G. P. S. Miguel, J. L. M. C. Azevedo, C. Gicovate, C. L. C. B. Neto, E. C. Moreira, P. S. Viana, Glucose homeostasis and weight loss in morbidly obese patients undergoing banded sleeve gastrectomy: a prospective clinical study. Clinics 20096410938
20 - J. B. Dixon, P. E. O’Brien, J. Playfair, L. Chapman, L. M. Schachter, S. Skinner, et al.Adjustable gastric banding and conventional therapy for the type 2 diabetes: a randomized controlled trial. JAMA. 200829931623
21 - N. Scopinaro, G. F. Adami, G. M. Marinari, E. Gianetta, E. Traverso, et al.diversion. Biliopancreatic, J. World, Surg, 199822936946
22 - P. R. Schauer, B. Burguera, S. Ikramuddin, D. Cottam, W. Gourash, G. Hamad, et al.Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 20032384467485
23 - D. E. Cummings, J. Overduin, K. E. Foster-Schubert, Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 20048926082615
24 - F. Rubino, A. Forgione, D. E. Cummings, M. Vix, D. Gnuli, G. Mingrone, et al.The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006244741749
25 - H. Buchwald, Y. Avidor, E. Braunwald, M. D. Jensen, W. Pories, K. Fahrbach, al. . et, surgery. a. Bariatric, review. systematic, J. A. M. meta-analysis, JAMA. 200429217241737
26 - P. S. Carvalho, M. C. Barelli, C. L. C. B. Moreira, F. H. Oliveira, M. F. Guzzo, G. P. S. Miguel, et al.Can bariatric surgery cure metabolic syndrome? Arq Bras Endocrinol e Metab 20075117985
27 - M. K. Cavaghan, D. A. Ehrmann, K. S. Polonsky, Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest. 2000106632933
28 - B. L. Wajchenberg, Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 200728187218
29 - E. E. Mason, The mechanism of surgical treatment of type 2 diabetes. Obes Surg. 200515459461
30 - M. V. D. Martins, A. A. P. Souza, Mecanismos cirúrgicos de controle do diabetes mellitus tipo 2 após cirurgia bariátrica. Rev Col Bras Cir. 2007345343346
31 - F. B. Langer, M. A. Reza, A. Hoda, F. X. Bohdjalian, J. Felberbauer, E. Zacherl, et. Wenzl, al, Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg 200515710249
32 - M. Nakazato, N. Murakami, Y. Date, M. Kojima, H. Matsuo, K. Kangawa, al. A. et, A role for ghrelin in the central regulation of feeding, Nature. 20014091948
33 - W. J. Pories, R. J. Albrecht, Etiology of type II diabetes mellitus: role of the foregut. World J Surg. 200125527531
34 - D. J. Drucker, Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002122531544
35 - Sociedade Brasileira de Diabetes. Diretrizes: tratamento e acompanhamento do diabetes mellitus.2007Diagraphic editora.
36 - M. Deitel, K. Gawdat, J. Melissas, Reporting weight loss 2007Obes Surg17565568
37 - J. Cai, C. Zheng, L. Xu, D. Chen, X. Li, J. Wu, et al.Therapeutic effects of sleeve gastrectomy plus gastric remnant banding on weigth reduction and gastric dilatation: na animal study. Obes Surg. 20081814117
38 - A. J. Greenstein, A. J. Vine, B. P. Jacob, When sleeve gastrectomy fails: adding a laparoscopic adjustable gastric band to increase restriction. Surg Endosc. 2009Epub ahead of print.
39 - I. Braghetto, O. Korn, H. Valladares, L. Gutiérrez, A. Csendes, A. Debandi, et al.sleeve. Laparoscopic, surgical. gastrectomy, indications. technique, results. clinical, Obes Surg. 200717144250
40 - K. Meirelles, T. Ahmed, D. M. Culnan, C. J. Lynch, C. H. Lang, R. Cooney, Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat. Ann Surg. 200924927785
41 - F. Diamond, The endocrine function of adipose tissue. Growth: genetics & hormones 2002181722
42 - C. M. Steppan, S. T. Bailey, S. Bhat, E. J. Brown, R. R. Banerjee, C. M. Wrigt, et al.The hormone resistin links obesity to diabetes. Nature. 2001409307312
43 - Available in:<> Accessed on May 2, 2011.
44 - J. B. Dixon, P. E. O’Brien, J. Playfair, L. Chapman, L. M. Schachter, S. Skinner, J. Proietto, M. Bailey, M. Anderson, Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008Jan 23;2993316323
45 - Z. Kim, K. Y. Hur, Laparoscopic mini-gastric bypass for type 2 diabetes: the preliminary report. World J Surg. 2011Mar;353631636
46 - W. J. Lee, K. Chong, K. H. Ser, Y. C. Lee, S. C. Chen, J. C. Chen, M. H. Tsai, L. M. Chuang, Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011Feb;1462143148